Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans

British Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2003, Pages 321-326

  Graff, Jochen ^a   Klinkhardt, Ute ^a   Westrup, Dagmar ^b   Kirchmaier, Carl M ^b   Breddin, Hans Klaus ^c   Harder, Sebastian ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^c International Institute of Thrombosis and Vascular Diseases   (Germany)

Author keywords

Aspirin; GPIIb IIIa receptor; Heparin; Interaction; YM337

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; CD62 ANTIBODY; COLLAGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; MONOCLONAL ANTIBODY; PAC1 ANTIBODY; PLACEBO; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG; YM 337;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BLEEDING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE AGGREGATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASPIRIN; BLEEDING TIME; DRUG INTERACTIONS; E-SELECTIN; FEMALE; HEPARIN; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN-TYROSINE-PHOSPHATASE;

EID: 0042318865     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2003.01873.x     Document Type: Article

References (36)

1. Kong DF, Califf RM, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829-2835.
2. Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734-741.
3. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.
4. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'. J Clin Invest 1996; 98: 863-874.
5. Harder S, Kirchmaier CM, Krzywanek J, Westrup D, Bae JW, Breddin HK. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM 337) in healthy subjects. Circulation 1999; 100: 1175-1182.
6. Rao AK, Sun L, Hiramatsu Y, Gorman JH 3rd, Edmunds LH Jr. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons. Thromb Haemost 1999; 82: 140-144.
7. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-256.
8. Mascelli MA, Kleiman NS, Marciniak SJ Jr, Damaraju L, Weisman HF, Jordan RE. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J 2000; 139: 696-703.
9. Harrington RA, Kleiman NS, Granger CB, Ohman EM, Berkowitz SD. Relation between inhibition of platelet aggregation and clinical outcomes. Am Heart J 1998; 136: S43-S50.
10. Nicholson NS, Panzer-Knodle SG, Haas NF et al. Assessment of platelet function assays. Am Heart J 1998; 135: S170-S178.
11. Modi NB, Novotny W, Reimann JD, Cannon CP, Braunwauld E. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome. J Clin Pharmacol 1999; 39: 675-684.
12. Greenberg HE, Wissel P, Barrett J et al. Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers. J Clin Pharmacol 2000; 40: 496-507.
13. Klinkhardt U, Breddin HK, Esslinger HU, Haas S, Kalatzis A, Harder S. Interaction between the LMWH reviparin and aspirin in healthy volunteers. Br J Clin Pharmacol 2000; 49: 337-341.
14. Klinkhardt U, Kirchmaier CM, Westrup D et al. Ex vivo-in vitro interaction between aspirin, clopidogrel and the glycoprotein IIb/IIIa-inhibitors abciximab and SR121566A. Clin Pharm Ther 2000; 67: 305-313.
15. Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Breddin HK, Harder S. Pharmacodynamic characterisation of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in humans. Br J Clin Pharmacol 2001; 52: 297-305.
16. Chen J, Sylvén C. Heparin potentiation of collagen-induced platelet aggregation is related to the GPIIbIIIa receptor and not to the GPIb receptor, as tested by whole blood aggregometry. Thromb Res 1992; 66: 111-120.
17. Fernandez F, N'guyen P, Van Ryn J. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-495.
18. Westwick J, Scully MF, Poll C, Kakkar VV. Comparison of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res Suppl 1986; 42: 435-447.
19. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001; 119: 64S-94S.
20. Harrington RA, Kleiman NS, Kottke-Marchant K et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222-1227.
21. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97: 1680-1688.
22. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-1497.
23. Umemura K, Kondo K, Ikeda Y, Nakashima M. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the IIb/IIIa inhibitor tirofiban. Thromb Haemost 1997; 78: 1381-1384.
24. Wittke B, Ensor H, Chung J et al. Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. Br J Clin Pharmacol 2000; 49: 231-239.
25. Clemetson KJ. Primary haemostasis: sticky fingers cement the relationship. Curr Biol 1999; 11: R110-R112.
26. Sakariassen KS, Barstad RM. Mechanisms of thromboembolism at arterial plaques. Blood Coagul Fibrinolysis 1993; 4: 615-625.
27. Barnes MJ, Knight CG, Farndale KW. The collagen-platelet interaction. Curr Opin Hematol 1998; 5: 314-320.
28. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha (q)-deficient mice. Nature 1997; 389: 183-186.
29. Nakamura T, Kambayashi J, Okuma M, Tandon NN. Activation of the GP IIb-IIIa complex induced by platelet adhesion to collagen is mediated by both alpha2beta1 integrin and GP VI. J Biol Chem 1999; 274: 11897-11903.
30. Freed MI, Boike S, Zariffa N, Jorkasky DK. Effect of acetylsalicylic acid on inhibition of ex vivo platelet aggregation and secretion by SKF 107260, a novel GPIIb/IIIa receptor antagonist. Thromb Haemost 1994; 72: 622-626.
31. Schini-Kerth VB, Bassus S, Fisslthaler B, Kirchmaier CM, Busse R. Aggregating human platelets stimulate the expression of thrombin receptors in cultured VSMC via the release of transforming growth factor β1 and platelet derived growth factor AB. Circulation 1997; 96: 3888-3896.
32. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Blood 1990; 75: 550-554.
33. Klinkhardt U, Graff J, Harder S, Clopidogrel, but not abciximab reduces platelet-leukocyte conjugates and P-selectin expression in a human ex vivo-in vitro model. Clin Pharmacol Ther 2002; 71: 176-185.
34. Gregorini L, Marco J, Fajadet J et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 1997; 29: 13-20.
35. Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996; 94: 279-285.
36. Rupprecht HJ, Darius H, Borkowski U et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998; 97: 1046-1052.